[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100323577":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":50,"collaborators":52,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":24,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Volunteer Group","EXPERIMENTAL","The healthy volunteer group will receive the same interventions as the ILD documented diagnosed volunteer group",[13],"Drug: Cu-DOTA-ECL1i",{"label":15,"type":10,"description":16,"interventionNames":17},"ILD Documented Diagnosed Volunteer Group","The ILD documented diagnosed volunteer group will receive the same interventions as the healthy volunteer group",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Cu-DOTA-ECL1i","Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Steven Brody, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","314-362-8969","brodys@wustl.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-90.19789,38.62727,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[53,56],{"name":54,"class":55},"National Institutes of Health (NIH)","NIH",{"name":57,"class":55},"National Heart, Lung, and Blood Institute (NHLBI)","100323577","early-phase-1-pet-imaging-ccr2-in-lung-inflammation-100323577",false,"NCT03492762","PET Imaging CCR2 in Lung Inflammation","Inclusion Criteria:\n\n* Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1\u002F2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month.\n* Screening FEV1 and FVC \\> 80% of predicted\n* Capable of lying still and supine within the PET\u002FCT and PET\u002FMR scanner for \\~1 hour and follow instructions for breathing protocol during the CT portion\n* No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year\n* No known history of cardiac, pulmonary, hepatic or renal disease or diabetes\n* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions\n* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol\n* BMI ≤ 35\n\nExclusion Criteria:\n\n* Currently enrolled in another study using an investigational drug\n* Pregnancy (confirmed by urine pregnancy test)\n* Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes\n* Currently taking any prescription medications\n* Presence of an implanted device that is incompatible with CT or MRI scanning\n* Creatinine \\> 1.30 mg\u002FdL, AST \\> 50 Units\u002FL, ALT \\> 55 Units\u002FL, or total bilirubin \\> 1.2 mg\u002FdL",true,"ALL","21 Years",{"count":68,"type":69},110,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.",[75],"Lung Inflammation","2026-04-29",{"date":78,"type":79},"2026-05-01","ACTUAL",{"date":81,"type":79},"2018-02-27",{"date":83,"type":69},"2027-12-31",{"name":5,"class":6},1]